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Caloric Restriction and Exercise Increase Plasma ANGPTL4
Levels in Humans via Elevated Free Fatty Acids
Sander Kersten, Laeticia Lichtenstein, Emma Steenbergen, Karin Mudde, Henk F.J. Hendriks,
Matthijs K. Hesselink, Patrick Schrauwen, Michael Mu¨ller
Objective—Plasma lipoprotein levels are determined by the balance between lipoprotein production and clearance.
Recently, angiopoietin-like protein 4 (ANGPTL4) was uncovered as a novel endocrine factor that potently raises plasma
triglyceride levels by inhibiting triglyceride clearance. However, very little is known about ANGPTL4 in human. Here
we set out to identify physiological determinants of plasma ANGPTL4 levels in humans, focusing on the effect of
energy restriction and plasma FFAs.
Methods and Results—We developed an ELISA for quantitative measurement of ANGPTL4 in human plasma. Using this
assay we found major variations in baseline plasma ANGPTL4 levels between individuals. Within an individual, plasma
ANGPTL4 levels remain stable throughout the day but increase significantly in response to long-term fasting, chronic
caloric restriction, and endurance exercise. Intralipid injection as well as treatment with a -adrenergic agonist, both of
which lead to elevated plasma FFA levels, increased plasma ANGPTL4 levels compared to control treatment. Fatty
acids markedly induced ANGPTL4 gene expression in rat hepatoma FAO cells, human primary myocytes, and mouse
intestinal MSIE cells.
Conclusion—In conclusion, our results show that plasma ANGPTL4 levels are increased by fasting, caloric restriction, and
exercise, which is likely mediated by elevated plasma FFAs. (Arterioscler Thromb Vasc Biol. 2009;29:969-974.)
Key Words: ANGPTL4  free fatty acids  caloric restriction
Changes in plasma lipoproteins are known to affectatherosclerosis and associated coronary heart disease
(CHD). Indeed, it is well established that elevated plasma
low-density lipoprotein (LDL) concentrations increase the
risk for CHD, whereas elevated high-density lipoprotein
(HDL) concentrations are considered atheroprotective.
Plasma lipoprotein levels are determined by the balance
between lipoprotein production and clearance. Recently,
angiopoietin-like protein 4 (ANGPTL4) was uncovered as a
novel endocrine factor that impacts plasma lipoprotein levels.
ANGPTL4, which is also referred to as fasting-induced
adipose factor Fiaf, is a secreted protein of about 50 kDa
that belongs to the family of angiopoietin-like proteins.1
ANGPTL4 was discovered by screening for target genes of
the peroxisome proliferators activated receptors alpha and
gamma, which serve as the molecular targets of the hypolipi-
demic fibrate and the insulin sensitizing thiazolidinedione
drugs, respectively.2,3 In mice, ANGPTL4 is produced by a
number of tissues including adipose tissue, liver, skeletal
muscle, heart, skin, and intestine.
Evidence abounds that ANGPTL4 plays a major role in the
regulation of lipid metabolism.4 ANGPTL4 inhibits the en-
zyme lipoprotein lipase, thereby suppressing clearance of
TG-rich lipoproteins and thus raising plasma TG levels.5
Inhibition of LPL occurs by inducing dissociation of catalyt-
ically active LPL dimers into inactive LPL monomers.6
Experiments with transgenic mice overexpressing ANGPTL4
suggest that ANGPTL4 inhibits LPL via paracrine and
endocrine signaling.7–10 Furthermore, ANGPTL4 stimulates
adipose tissue lipolysis, leading to elevation of plasma free
fatty acid levels.5,10,11 Analogous to numerous other pro-
tein hormones, ANGPTL4 is proteolytically processed to
produce N-terminal and C-terminal fragments that can be
detected in human serum.12,13 Processing seems to occur in
a tissue-specific manner. Indeed, the liver actively cleaves
ANGPTL4, whereas human adipose tissue shows no pro-
teolytic activity.12
In addition to governing clearance of plasma lipoproteins,
ANGPTL4 has been suggested to play a role in angiogenesis.
It has been shown that ANGPTL4 is a structural and likely
regulatory component of the extracellular matrix that affects
numerous aspects of endothelial function including angiogen-
esis, endothelial cell migration, vascular leakage, and cell
adhesion.14–19
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Presently, very limited information is available about
ANGPTL4 in human. It has been shown that carriers of a rare
sequence variant of the ANGPTL4 gene have elevated
plasma HDL and decreased TG levels.20 However, because of
the absence of a commercial assay to quantitatively assess
ANGPTL4, very little is known about plasma ANGPTL4
levels in human. Here, we describe the development, valida-
tion, and application of a novel ELISA for quantitative
determination of ANGPTL4 in human plasma. We used this
newly developed ELISA to identify physiological determi-
nants of plasma ANGPTL4, focusing on the role of fasting
and plasma FFAs.
Materials and Methods
For detailed information on the human interventions, Western blot,
and quantitative RT-PCR, please see the supplemental materials
(available online at http://atvb.ahajournals.org).
ELISA
96-well microtiter plates were coated with the antihANGPTL4
polyclonal goat IgG antibody (AF3485, R&D Systems) at 0.16
g/well and incubated overnight at 4°C. This antibody was obtained
by immunization of goats with NS0-derived recombinant human
angiopoietin-like 4 (AA 26 to 406). After 4 washes with 300 L
PBS-Tween20 0.1% (washing buffer), 300 L of blocking solution
(PBS containing 1% BSA) was added per well and left for 1 hour at
room temperature under gentle agitation. 100 L of 20-fold diluted
human plasma was applied to each well, followed by 2-hour
incubation at room temperature under gentle agitation. A standard
curve of increasing amounts of recombinant human ANGPTL4
(3485-AN, R&D Systems) was prepared (0.3 to 2.1 ng/well) in
TBS-Tween20 0.5%, containing 0.1% BSA, and incubated under
similar conditions. After rinsing 4 times with washing buffer, 100 L
of diluted biotinylated anti-hANGPTL4 polyclonal goat IgG anti-
body (BAF3485, R&D Systems) was added at 0.02 g per well,
followed by another 2-hour incubation. After rinsing 4 times with
washing buffer, streptavidine-conjugated horseradish peroxidase was
added for 1 hour. After, rinsing 4 times with washing buffer,
subsequent reaction with tetramethyla-benzidine substrate reagent
was allowed to proceed for 6 minutes. The reaction was stopped by
addition of 50 L of 10% H2SO4, and the absorbance was measured
at 450 nm on a MultiSkan Ascent spectrophotometer (Thermo
Scientific, Breda, the Netherlands).
The ELISA assay used is virtually identical to the DuoSet Elisa
hANGPTL4 offered commercially by R&D systems with several
minor modifications. Importantly, absorbance values remain within
the linear range of the standard curve, which does not exceed 2.1
ng/mL.
Cell Culture
Partially confluent HepG2 cells were transfected with a GFP control
vector (pEGFP-N2) or the expression vector pcDNA3.1/V5-HisA
encoding mAngptl4 or hANGPTL4. After transfection, cells were
incubated in serum-free DMEM. 24 hours posttransfection, medium
and cell lysates were collected and used for ANGPTL4 Elisa assay.
Human primary myocytes were prepared from 3 individuals as
previously described.28 Rat hepatoma FAO cells, human primary
myocytes, and mouse intestinal MSIE cells were grown in DMEM
containing 10% (vol/vol) fetal bovine serum, 100 U/mL penicillin
and 100 g/mL streptomycin. Cells were incubated with albumin
only (control), albumin-bound oleic or linoleic acid (100 mol/L), or
synthetic PPAR agonists for 24 hours, followed by RNA isolation
and qRT-PCR. Wy14643 was used at a concentration of 5 mol/L
(FAO, MSIE). GW501516 was used at 1 mol/L (FAO, MSIE) or
10 mol/L (primary myocytes), and TTA (Tetradecylthioacetic
Acid) was used at 100 mol/L.
Results
To better characterize ANGPTL4 in human, we first deter-
mined ANGPTL4 gene expression levels in a large number of
human tissues. In general, ANGPTL4 expression was rela-
tively ubiquitous. Highest expression levels were found in
liver, followed by adipose tissue, thyroid, brain, and small
intestine (Figure 1).
To better understand the role of ANGPTL4 in human, we
developed an ELISA assay to quantitatively assess serum or
plasma ANGPTL4 levels in human subjects. A standard
curve was generated using recombinant human ANGPTL4,
showing a clear linear relationship between ANGPTL4 con-
centration and absorbance at 450 nm (Figure 2A). As shown
by Western blot, the antibody used in the ELISA detected a
single band at 50 kDa, corresponding to the molecular weight
of full-length ANGPTL4 (Figure 2B). The same band and an
additional band corresponding to the N-terminal truncated
portion of ANGPTL4 were detected using an antibody
directed against a N-terminal peptide-epitope (Figure 2C). To
test the specificity of the assay, HepG2 cells were transiently
transfected with expression vectors encoding mouse Angptl4,
human ANGPTL4, or EFGP, and cells and medium were
harvested 24 hours thereafter. ANGPTL4 was specifically
detected in medium and cell lysate of HepG2 cells transfected
with hANGPTL4, indicating the absence of any cross-
reactivity with mAngptl4 (Figure 2D). As a final verification,
we confirmed the increase in plasma ANGPTL4 levels in
patients after treatment with the PPAR agonist fenofibrate
(Figure 2E), as previously demonstrated by semiquantitative
Western blot.12
We first determined a number of basic characteristics of
the hANGPTL4 ELISA assay. The intraassay coefficient of
variation (CV) for the assay was determined at 6.8%. The
within-subject intraday CV, which was determined by mea-
suring plasma ANGPTL4 levels at numerous time points
throughout the day, was slightly higher at 10%, whereas the
within-subject interday CV was similarly low at 14%. In
contrast to the low variability within subjects, we found a
large interindividual variation in plasma ANGPTL4 levels, as
shown by a between-subject CV of 78%. These data indicate
Figure 1. Expression profile of ANGPTL4 mRNA in human tis-
sues. The FirstChoice Human Total RNA Survey Panel (Ambion)
was reverse transcribed and used for qPCR using primers spe-
cific for human ANGPTL4. Expression levels are expressed rela-
tive to liver, which showed the highest expression level (100%).
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that plasma ANGPTL4 levels are relatively constant within
an individual, yet differ markedly between subjects.
As plasma ANGPTL4 levels were highly variable between
individuals, we were interested to study the potential rela-
tionship with plasma TG, which have been shown to be
impacted by ANGPTL4 overexpression or deletion in mice.
Interestingly, in a samples of 36 middle-aged women (study
2), we did not find any association between plasma AN-
GPTL4 and plasma TG levels (data not shown). Similarly, no
association was found with BMI or other plasma metabolic
parameters such as insulin, glucose, and adiponectin.
In an effort to ascertain the physiological determinants of
plasma ANGPTL4 levels, we first determined the circadian
rhythm of plasma ANGPTL4 in 9 subjects who took their
meals at specific times. While normal postprandial responses
in plasma free fatty acids and glucose were observed (Figure
3A and 3B), plasma ANGPTL4 levels remained remarkably
stable (Figure 3C). As mentioned above, however, major
variation in plasma ANGPTL4 levels was observed between
subjects.
To metabolically challenge subjects, 4 young males fasted
for 48 hours.23 Plasma ANGPTL4 levels went up in all
individuals (Figure 4A, mean relative increase: 80%,
P0.01). Plasma ANGPTL4 also significantly increased in
obese patients subjected to 25 days of severe food deprivation
(Figure 4B, mean relative increase: 79%, P0.001).24 These
data indicate that plasma ANGPTL4 levels increase in re-
sponse to both short-term and long-term energy restriction,
which are associated with elevated plasma FFA levels (sup-
plemental Figure I).
Expression of ANGPTL4 in numerous tissues was highly
sensitive to free fatty acids, as shown by dramatic induction
of ANGPTL4 mRNA by the fatty acids oleic acid and linoleic
acid in rat FAO hepatoma cells, primary human myocytes,
and mouse intestinal MSIE cells (Figure 5). ANGPTL4
induction was mimicked by synthetic agonists of PPARs,
which serve as receptors for fatty acids, indicating a role for
PPARs. These data suggest that the effect of severe energy
restriction on plasma ANGPTL4 may be mediated by ele-
vated plasma FFAs.
Another physiological stressor that increases plasma FFA
is endurance exercise. Remarkably, we found that fasting
plasma ANGPTL4 levels further increased during endurance
exercise and especially during subsequent recovery, concur-
Figure 2. Characteristics of the ANGPTL4 Elisa assay. A, Stan-
dard curve showing linear relationship between concentration of
ANGPTL4 protein and absorbance. Plasma samples were
diluted 20- to 50-fold to fall within the linear range. B, Western
blot of human blood plasma using the same antibody as used in
the Elisa assay. C, Western blot of human blood plasma using
an antibody directed against a N-terminal epitope of ANGPTL4.12
Same individuals are shown as in panel B. D, Concentration of
ANGPTL4 in medium and cell lysate of HepG2 cells 24 hours
after transfection with GFP control vector or expression vector
encoding ANGPTL4. E, Plasma ANGPTL4 levels in 25 individu-
als before and after 4 weeks of fenofibrate treatment (study 1).12 Figure 3. Plasma ANGPTL4 shows little diurnal variation. Blood
plasma was sampled from 9 subjects before, after, and
in-between meals for measurement of FFA (A), glucose (B), and
ANGPTL4 (C; study 3). Dotted lines represent plasma ANGPTL4
levels of individual subjects. Straight lines represent means of 9
subjects. Error bars represent SD.
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rent with an increase in plasma FFAs (Figure 6A and
supplemental Figure II).25 Importantly, the increase in plasma
ANGPTL4 was entirely abolished when subjects were given
oral glucose, which elicits insulin release and thereby sup-
presses plasma FFA levels. To further explore the impact of
plasma FFA, plasma ANGPTL4 levels were measured in
subjects who underwent a hyperinsulinemic clamp while
receiving an infusion of either glycerol (control) or lipids
together with heparin, which causes a massive increase in
plasma FFAs (Supplemental Figure II).26 Whereas plasma
ANGPTL4 declined significantly on control treatment, which
may reflect a direct effect of insulin or may be attributable to an
insulin-induced suppression of plasma FFAs, the decrease in
plasma ANGPTL4 was significantly diminished after lipid
infusion (Figure 6B). Similarly, treatment with the
Figure 4. Plasma ANGPTL4 levels are increased by fasting and
caloric restriction. A, Plasma ANGPTL4 was measured in 4 sub-
jects after a meal, and after 24 hours or 48 hours of fasting
(study 4). B, ANGPTL4 levels were measured in overnight fast-
ing plasma from 22 overweight males before and after 25 days
of caloric restriction (study 5).
Figure 5. Fatty acids markedly induce
ANGPTL4 mRNA. Cultured cells were
incubated with oleic or linoleic acid,
Wy14643, GW501516, or tetradecylthio-
acetic acid (TTA) for 24 hours, followed
by RNA isolation and qRT-PCR.
CYP4A14 or ADFP served as positive
PPAR control genes. Error bars repre-
sent SEM. *Significantly different accord-
ing to Student t test (P0.05).
Figure 6. Plasma ANGPTL4 levels increase during exercise in
fasted but not fed state. A, After overnight fasting, 7 subjects
performed 2 hours of endurance exercise followed by 4 hours of
postexercise recovery while fasted (gray bar) or with glucose
ingestion (white bar; study 6). To normalize for large differences
in baseline ANGPTL4 values, levels are shown as % change
over baseline (fasted state, preexercise). B, Plasma ANGPTL4
levels were determined in 9 subjects before (baseline) and after
a 6-hour hyperinsulinaemic-euglycaemic clamp with simulta-
neous infusion of either glycerol or lipid emulsion (study 7). The
percentage change in plasma ANGPTL4 from 0 to 6 hours is
shown. C, Plasma ANGPTL4 levels in 9 males before (baseline)
and after receiving a 3-hour infusion of salbutamol with or with-
out simultaneous administration of acipimox (study 8). The per-
centage change in plasma ANGPTL4 from 0 to 3 hours is
shown. Error bars represent SEM. *Significantly different accord-
ing to Student t test (P0.05).
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-adrenergic agonist salbutamol, which causes a marked
increase in plasma FFA (Supplemental Figure II),27 signifi-
cantly raised plasma ANGPTL4 levels. This response was
entirely blunted when subjects were simultaneously given
acipimox, a lipolysis inhibitor that reduces plasma free fatty
acids (Figure 6C). These data suggest that plasma FFAs
increase plasma ANGPTL4 levels.
Discussion
Very little is known about determinants of plasma ANGPTL4
levels in humans. Our data point to a large interindividual
variation in plasma ANGPTL4 levels. In contrast, plasma
ANGPTL4 levels are very constant within an individual,
which is true during normal circadian rhythm as well as
between days. From our data it is evident that major physi-
ological stressors such as fasting and exercise are required to
elicit significant changes in plasma ANGPTL4. Specifically,
we observed that 48 hours of fasting and 25 days of severe
caloric restriction both raised plasma ANGPTL4 by an
average of 80%. Fasting plasma ANGPTL4 levels were
further stimulated by endurance exercise and postexercise
recovery. Additional experiments indicated that the increase
in plasma ANGPTL4 levels is likely mediated by elevated
FFAs via activation of ANGPTL4 gene transcription via PPARs.
Alternatively, it may be argued that instead of or in addition to
FFAs raising plasma ANGPTL4, ANGPTL4 may raise plasma
FFAs via stimulation of adipose tissue lipolysis. Studies using
Angptl4 knock-out or transgenic mice,10 as well as i.v.
injection of recombinant Angptl45 support a potent prolipo-
lytic activity of ANGPTL4 in adipose tissue. It is possible
that both mechanism operate in concert as part of a positive
feedback loop.
The increase in plasma ANGPTL4 levels during fasting is
in line with a wealth of mouse data showing induction of
Angptl4 gene expression by fasting in numerous tis-
sues.2,10,11,29,30 By inhibiting lipolysis of TG-rich lipoproteins,
which results in decreased tissue uptake of plasma TG-
derived fatty acids, while at the same time increasing plasma
FFAs by stimulating adipose tissue lipolysis, we hypothesize
that ANGPTL4 may cause a shift in overall fuel use from
plasma TG toward TG stored in the adipose tissue. Depend-
ing on whether the tissue primarily uses plasma TG-derived
fatty acids or FFA,31 ANGPTL4 upregulation is expected to
either cause a decrease or increase in net fatty acid uptake.
Upregulation of ANGPTL4 by fasting may thus be aimed at
promoting use of fat in favor of fat storage. This mechanism
may be supported by the above-mentioned positive feedback
loop in which ANGPTL4 stimulates release of FFAs, which
in turn stimulates ANGPTL4 production.
Depending on the type of tissue involved, the effect of fatty
acids on ANGPTL4 mRNA can be mediated by different
PPAR isotypes. Our results suggest that fatty acids induce
ANGPTL4 mRNA via PPAR in rat hepatoma cells and via
PPAR/ in mouse intestinal cells MSIE cells. In human
myocytes, both PPAR and PPAR/ likely play a role in
ANGPTL4 gene induction by fatty acids.
Using semiquantitative Western Blot, we previously showed
that 4 weeks of treatment with the PPAR agonist fenofibrate
significantly raised plasma levels of the N-terminal ANGPTL4
fragment.12 Our present ELISA data similarly reveal a
marked increase in plasma levels of full-length ANGPTL4 on
fenofibrate treatment. As fibrates primarily target liver, these
data suggest that liver is the most important source of plasma
ANGPTL4, which is supported by the dominant expression of
ANGPTL4 in human liver.
Previously, Xu and colleagues found that plasma ANGPTL4
levels were decreased in obese diabetics compared to obese
nondiabetics or normal weight individuals.7 It should be
emphasized that, in contrast to the antibody used by Xu and
colleagues, the antibody used in our ELISA specifically
detects the full-length ANGPTL4 protein and does not
recognize any of the truncated variants of ANGPTL4. It is
known that ANGPTL4 is cleaved into N- and C-terminal
fragments of about equal size, which may each carry an
entirely different function.12 N-terminal ANGPTL4 has been
shown to potently inhibit lipoprotein lipase, whereas
C-terminal ANGPTL4 influences endothelial cell migration
and function, possibly via suppressing the Raf/MEK/ERK
signaling cascade.32 Future research will have to better
address possible changes in full-length ANGPTL4 in diabetic
patients.
Because Angptl4 overexpression markedly elevates plasma
TG levels in mice,7–10 it is of interest to study whether in
humans a positive correlation may exist between plasma
ANGPTL4 and plasma TG levels. In a limited sample of 36
women, we could not find such a correlation, nor between
plasma ANGPTL4 and other metabolic parameters. Although
these data might argue against a major impact of ANGPTL4
on plasma TG levels in humans, recent studies indicate that a
rare sequence variant of ANGPTL4 that gives rise to a
dysfunctional protein is associated with decreased plasma TG
levels.20,33–35 More extensive investigations using large cohorts
will need to be carried out to further explore the relation between
plasma ANGPTL4 and various plasma lipid parameters.
In conclusion, our data show major variation in plasma
ANGPTL4 levels between individuals. Within an individual,
plasma ANGPTL4 levels remain stable throughout the day
but increase in response to fasting, chronic caloric restriction,
and endurance exercise. Long-term changes in plasma AN-
GPTL4 levels are likely mediated by changes in plasma FFA,
which potently raise ANGPTL4 gene expression.
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Supplemental methods 
Human interventions 
Study 1: Blood was taken after an overnight fast from 25 male mildly hyperlipidemic subjects before 
and after a 4-week treatment with 250 mg of micronized fenofibrate daily. All subjects had significant 
coronary artery disease as documented by angiography 21. 
 
Study 2: A fasting blood sample was taken in 36 apparently healthy post-menopausal women varying 
in body mass index from 20.7 to 35 kg/m2 (age: 56.5±4.2 years, BMI: 25.4±3.3 kg/m2, fasting glucose: 
5.5 ±0.4 mM). The women participated in a randomised, open label, placebo-controlled trial that 
investigated the effects of daily wine or grape juice consumption on markers of insulin sensitivity. 
Blood samples were obtained from the antecubital vein of the forearm and collected in EDTA-coated 
tubes 22. 
 
Study 3: Two male and seven female subjects between the age of 24 and 32 years came to the 
laboratory in fasted state (BMI: 19.1–26.6, mean 22.4 kg/m2; fasting glucose: 4.8 ±0.6 mM). Blood 
samples were taken via finger prick at selected time before, after and in between meals. Subjects 
maintained their normal pattern of activities including meal choice. 
 
Study 4: Four healthy male volunteers, between 19 and 22 years of age (mean 20.6), were recruited 
from the Wageningen student population (age:19-22, mean 20.6; BMI: 20.4–22.6, mean 21.3 kg/m2; 
fasting glucose: 4.9–5.7, mean 5.2 mM). Volunteers received an identical meal at 17.00, before the 
start of a 48-h fasting period. At baseline and after 24h and 48 h of fasting, blood was drawn from the 
antecubital vein of the forearm into EDTA-coated tubes 23. 
 
Study 5: Participants were overweight men with a mean (± SEM) age of 34.8±1.3 y and body mass 
index (in kg/m2) of 28.8±0.5. All 22 subjects reduced their energy intake to 2.1 MJ/d by means of a 
very-low-energy diet for the duration of 25 days. Fasting blood samples were obtained from the 
antecubital vein of the forearm and collected in EDTA-coated tubes 24. 
 
Study 6: Seven healthy, untrained male volunteers participated in the study (age: 22.7±0.6 years, BMI: 
23.8±1.0 kg/m2, height: 1.79±0.03 m, VO2max: 50.5±2.4 mL/min/kg). After an overnight fast, subjects 
came to the laboratory at 8:00 AM. After local anesthesia, a Teflon cannula was inserted in an 
antecubital vein for sampling of blood. Subjects rested on a bed, and a baseline blood sample was 
taken. Immediately thereafter, subjects ingested 1.4 g/kg bodyweight glucose or water. Subject 
exercised at 50% VO2 max for 2 h and then rested for 4 h. Blood was samples at regular intervals 
throughout the study. Also, at regular intervals subjects ingested 0.35 g/kg bodyweight glucose or 
water. All subjects underwent the experimental protocol two times, once with glucose ingestion and 
once while fasting 25. 
 
Study 7: Nine healthy lean male volunteers participated in the present study (age: 20.1±0.5 years, 
BMI: 21.7±0.6 kg/m2, bodyfat: 16.0±1.3%). All subjects underwent two euglycaemic–
hyperinsulinaemic clamps with 40 mU/m2/min insulin and variable co-infusion of a 20% glucose 
solution to reach a blood glucose level of ~5 mmol/L with simultaneous infusion of glycerol (73 
mL/h) or intralipid (81 mL/h) in randomised order. Test days were separated by at least 1 week. On 
both experimental days, subjects arrived at the laboratory at 8.00 h after an overnight fast. Blood was 
sampled at regular time points throughout the clamp 26. 
 
Study 8: Nine healthy lean male volunteers participated in this study (age: 24.4±1.3 years, BMI: 
22.2±0.8 kg/m2, height: 1.79±0.03 m). Upon arrival at the laboratory after an overnight fast, two 
Teflon cannulas were inserted into an antecubital vein of each arm. One cannula was used for the 
infusion of  β2-adrenergic agonist and one cannula for sampling of blood. A first blood sample was 
taken, followed by a continuous infusion of 77 ng/min/kgFFM salbutamol maintained for 3 h. In 
addition, two doses of 250 mg acipimox or placebo were given orally at –120 min and time 0. Blood 
samples were taken at regular intervals throughout the study 27. 
All human interventions were approved by the Medical Ethics Committee of the institute involved. 
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Electrophoresis and Western Blot 
0.25 µL of human plasma was separated by SDS-PAGE and transferred to immobilon-P membrane.  
Western blotting was carried out using an ECL system (GE Healthcare, Diegem, Belgium) according 
to the manufacturer's instructions. The primary antibody was used at a dilution of 1:2500, and the 
secondary antibody (anti-rabbit IgG, Sigma) was used at a dilution of 1:8000. All incubations were 
performed in 1x Tris-buffered saline, pH 7.5, with 0.1% Tween 20 and 5% dry milk, except for the 
final washings, when milk was omitted. Primary antibody was the same as used for Elisa or was a 
human polyclonal antibody directed against the epitope CQGTEGSTDLPLAPE 12. 
 
Quantitative PCR 
cDNA was prepared from FirstChoice® Human Total RNA Survey Panel (Ambion) using the iScript 
cDNA Synthesis Kit (Bio-Rad Laboratories BV, Veenendaal, The Netherlands). Real-Time PCR was 
carried out using platinum Taq polymerase (Invitrogen, Breda, the Netherlands) and SYBR green 
using an iCycler PCR machine (Bio-Rad Laboratories BV). Melt curve analysis was performed to 
assure a single PCR product was formed. hANGPTL4 cDNA was amplified using primers: 5’-
CACAGCCTGCAGACACAACTC-3’ and 5’-GGAGGCCAAACTGGCTTTGC-3’; m/rAngptl4 
cDNA was amplified using primers: 5’-GTTTGCAGACTCAGCTCAAGG-3’ and 5’-
CCAAGAGGTCTATCTGGCTCTG-3’. ANGPTL4 expression data were normalized against the 
housekeeping genes 36B4 (FAO, MSIE) or actin (primary myocytes). Primer sequences are available 
upon request. 
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Supplemental Figures 
 
 
Supplemental Figure I: Plasma FFA levels are increased by fasting and caloric restriction. A) FFA 
levels were measured in plasma sampled from four young healthy males right after a meal, and after 
24h or 48h of fasting (study 4). B) FFA levels were measured in overnight fasting plasma sampled 
from 22 healthy overweight males (BMI 25-32) before and after 25 days of subsisting on a protein-
enriched formula diet that provided 2.1 MJ/d (study 5). Error bars represent SEM. * = significantly 
different according to Student’s T-test (p<0.05). 
 
 
 
Supplemental Figure II: Plasma FFA levels increase during exercise in fasted but not fed state. A) 
After an overnight fast, seven subjects underwent a protocol of 2 hours of endurance exercise followed 
by 4 hours of post-exercise recovery either in the fasted state (grey bar) or with glucose ingestion 
(white bar) (study 6). Blood was samples at various time points for assessment of plasma FFA. B) 
Plasma FFA levels were determined in nine healthy lean male subjects after undergoing a 6-h 
hyperinsulinaemic–euglycaemic clamp with simultaneous infusion of either glycerol or a lipid 
emulsion (study 7). C) Plasma FFA levels were determined in nine lean males after receiving a 3-h 
infusion of salbutamol with or without simultaneous administration of acipimox (study 8). Error bars 
represent SEM. * = significantly different according to Student’s T-test (p<0.05). 
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